NO20043483L - Anvendelse av melagatran for fremstilling av et medikament for behandling av type 1 Diabetes mellitus - Google Patents

Anvendelse av melagatran for fremstilling av et medikament for behandling av type 1 Diabetes mellitus

Info

Publication number
NO20043483L
NO20043483L NO20043483A NO20043483A NO20043483L NO 20043483 L NO20043483 L NO 20043483L NO 20043483 A NO20043483 A NO 20043483A NO 20043483 A NO20043483 A NO 20043483A NO 20043483 L NO20043483 L NO 20043483L
Authority
NO
Norway
Prior art keywords
melagatran
drug
manufacture
treatment
type
Prior art date
Application number
NO20043483A
Other languages
English (en)
Inventor
Olle Korsgren
Bo Nilsson
Original Assignee
Astrazeneca Ab Global Ip
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab Global Ip filed Critical Astrazeneca Ab Global Ip
Publication of NO20043483L publication Critical patent/NO20043483L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Physiology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20043483A 2002-01-23 2004-08-20 Anvendelse av melagatran for fremstilling av et medikament for behandling av type 1 Diabetes mellitus NO20043483L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0200198A SE0200198D0 (sv) 2002-01-23 2002-01-23 New use
PCT/SE2003/000087 WO2003061682A1 (en) 2002-01-23 2003-01-21 The use of melagatran for the manufacture of a medicament for the treatment of type 1 diabetes mellitus

Publications (1)

Publication Number Publication Date
NO20043483L true NO20043483L (no) 2004-08-20

Family

ID=20286751

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20043483A NO20043483L (no) 2002-01-23 2004-08-20 Anvendelse av melagatran for fremstilling av et medikament for behandling av type 1 Diabetes mellitus

Country Status (14)

Country Link
US (2) US7045502B2 (no)
EP (1) EP1469874A1 (no)
JP (1) JP2005516035A (no)
KR (1) KR20040075096A (no)
CN (1) CN100430089C (no)
BR (1) BR0306798A (no)
CA (1) CA2472241A1 (no)
IL (1) IL162853A0 (no)
MX (1) MXPA04007192A (no)
NO (1) NO20043483L (no)
NZ (1) NZ533749A (no)
SE (1) SE0200198D0 (no)
WO (1) WO2003061682A1 (no)
ZA (1) ZA200405342B (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0200198D0 (sv) * 2002-01-23 2002-01-23 Astrazeneca Ab New use
SG10201502484SA (en) 2010-03-30 2015-05-28 Verseon Corp Multisubstituted aromatic compounds as inhibitors of thrombin
WO2014149139A2 (en) 2013-03-15 2014-09-25 Verseon, Inc. Halogenopyrazoles as inhibitors of thrombin
DK2968297T3 (en) 2013-03-15 2019-01-07 Verseon Inc MULTI-SUBSTITUTED AROMATIC COMPOUNDS AS SERINE PROTEASE INHIBITORS
JP2017528486A (ja) 2014-09-17 2017-09-28 ヴァーセオン コーポレイション セリンプロテアーゼ阻害剤としてのピラゾリル置換ピリドン化合物
ES2931460T3 (es) 2015-02-27 2022-12-29 Verseon Int Corporation Compuestos de pirazol sustituido como inhibidores de serina proteasa
IL280078B2 (en) 2018-07-13 2024-04-01 Verseon Int Corporation Thrombin inhibitors, formulations, and uses thereof
AU2022325955A1 (en) 2021-08-11 2024-02-08 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
WO2023158836A1 (en) 2022-02-17 2023-08-24 Sana Biotechnology, Inc. Engineered cd47 proteins and uses thereof
CN121843705A (zh) 2023-05-03 2026-04-10 萨那生物科技公司 工程化胰岛细胞的给药和施用方法
WO2024243236A2 (en) 2023-05-22 2024-11-28 Sana Biotechnology, Inc. Methods of delivery of islet cells and related methods
WO2025043172A1 (en) 2023-08-23 2025-02-27 Sana Biotechnology, Inc. Modified cd47 proteins and their uses

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9301916D0 (sv) 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
AR005245A1 (es) 1995-12-21 1999-04-28 Astrazeneca Ab Prodrogas de inhibidores de trombina, una formulación farmaceutica que las comprende, el uso de dichas prodrogas para la manufactura de un medicamento y un procedimiento para su preparacion
SE9900070D0 (sv) * 1999-01-13 1999-01-13 Astra Ab New use
SE523817C2 (sv) 1999-02-05 2004-05-18 Corline Systems Ab Användning av ett koagulationsförebyggande ämne i samband med transplantation av insulinproducerande celler
US6462021B1 (en) 2000-11-06 2002-10-08 Astrazeneca Ab Use of low molecular weight thrombin inhibitor
SE0200198D0 (sv) * 2002-01-23 2002-01-23 Astrazeneca Ab New use

Also Published As

Publication number Publication date
CN1729010A (zh) 2006-02-01
US20060148720A1 (en) 2006-07-06
KR20040075096A (ko) 2004-08-26
US20050090424A1 (en) 2005-04-28
BR0306798A (pt) 2004-12-07
CA2472241A1 (en) 2003-07-31
JP2005516035A (ja) 2005-06-02
MXPA04007192A (es) 2004-10-29
WO2003061682A1 (en) 2003-07-31
EP1469874A1 (en) 2004-10-27
SE0200198D0 (sv) 2002-01-23
US7045502B2 (en) 2006-05-16
CN100430089C (zh) 2008-11-05
IL162853A0 (en) 2005-11-20
ZA200405342B (en) 2005-09-28
NZ533749A (en) 2006-02-24

Similar Documents

Publication Publication Date Title
NO20053041D0 (no) Behandling av diabetes.
IL213809A0 (en) Use of derivatives of n-phenylpiperazin-1-yl-acetamide for the preparation of a pharmaceutical compositions for treatment of diabetes related conditions
NO20020764D0 (no) Benzoesyrederivater for behandling av diabetes mellitus
IL166058A0 (en) Novel thiophenylglycoside derivatives methods for production thereof medicaments comprising said compounds and use thereof
PL372865A1 (en) Aryl 5-thio-beta-d-glucopyranoside derivatives and remedies for diabetes containing the same
NO20053077D0 (no) Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer.
IS2793B (is) Notkun á 3-hýdroxý-3-metýlglútarýl hjálparensíms A afsýringarkljúfshindrum til framleiðslunnar á lyfi til að meðhöndla sykursýkitaugakvilla
ATE406162T1 (de) Pramipexol-tablette mit verzögerter wirkstoffabgabe
AU2003234529A8 (en) Glp-1 gene delivery for the treatment of type 2 diabetes
EG24124A (en) Pharmaceutical compositions for the treatment of type-II diabetes mellitus
IL210046A0 (en) Ccr1 antagonists for the treatment of i.a. demyelinating inflammatory disease
NO20022087L (no) Fremgangsmåte for behandling av diabetes
AU2003279442A8 (en) 2-thiohydantoine derivative compounds and use thereof for the treatment of diabetes
AU2003234929A1 (en) Therapeutic agent for diabetes
PL375964A1 (en) Use of indolyl derivatives for the manufacture of a medicament for the treatment allergic rhinitis
AU2003295890A1 (en) Anilinopyrazole derivatives useful for the treatment of diabetes
AU2003243708A1 (en) Use of bases for the manufacture of a medicament in the treatment of different forms of inflammatory dermatosis
IT1318514B1 (it) Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
AU2003252182A1 (en) Therapeutic treatment for the metabolic syndrome and type 2 diabetes
IL162853A0 (en) The use of melagatran for the manufacture of a medicament for the treatment of type 1 diabetes mellitus
AU2003203146A1 (en) Use of glp-1 compound for treatment of critically ill patients
AU2003303217A8 (en) Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
NO20032006L (no) Anvendelse av melagatran for fremstilling av et medikament for behandling av ischemiske lidelser
IL162509A (en) Use of deoxypeganine for the production of a drug for treating clinical depression
NO20025883L (no) Tiazolidinonsalt for behandling av diabetes mellitus

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application